Drug Profile
Salmosin
Latest Information Update: 29 Apr 2002
Price :
$50
*
At a glance
- Originator Nonindustrial sources
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 15 Sep 1999 New profile
- 15 Sep 1999 Preclinical development for Solid tumours in South Korea (Unknown route)